[{"id":"6d19b3f0-4cc5-4aec-9cc7-a1e6cef5690a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00924196","created_at":"2021-01-18T03:34:45.955Z","updated_at":"2025-02-25T12:25:33.732Z","phase":"","brief_title":"Natural History Study of Patients With Neurofibromatosis Type I","source_id_and_acronym":"NCT00924196","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 259","initiation":"Initiation: 02/25/2008","start_date":" 02/25/2008","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-24"},{"id":"a64e7059-51b9-4bf5-a1c3-321665846a5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02211768","created_at":"2021-01-18T10:21:36.289Z","updated_at":"2025-02-25T13:39:14.783Z","phase":"Phase 1","brief_title":"Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1","source_id_and_acronym":"NCT02211768","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 12/08/2014","start_date":" 12/08/2014","primary_txt":" Primary completion: 09/05/2017","primary_completion_date":" 09/05/2017","study_txt":" Completion: 12/30/2019","study_completion_date":" 12/30/2019","last_update_posted":"2025-02-21"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"46612199-ef89-461b-ba2d-66518055f785","acronym":"","url":"https://clinicaltrials.gov/study/NCT05985161","created_at":"2023-08-14T16:10:05.963Z","updated_at":"2025-02-25T16:40:04.331Z","phase":"Phase 2","brief_title":"A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors","source_id_and_acronym":"NCT05985161","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" XPO1","pipe":" | ","alterations":" XPO1 E571K • XPO1 mutation","tags":["XPO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e XPO1 E571K • XPO1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 08/01/2029","primary_completion_date":" 08/01/2029","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2025-02-06"},{"id":"a6924d5b-de24-40e2-b106-96da6cb8e6d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06693284","created_at":"2025-02-25T15:37:46.378Z","updated_at":"2025-02-25T15:37:46.378Z","phase":"Phase 1","brief_title":"A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]","source_id_and_acronym":"NCT06693284","lead_sponsor":"University of Minnesota","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gomekli (mirdametinib) • Zolinza (vorinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-01-14"},{"id":"9795b4cb-6f73-4ce5-a9a8-6ba8acc8d386","acronym":"Keynote MK-3475-B66","url":"https://clinicaltrials.gov/study/NCT03611868","created_at":"2021-01-18T17:45:12.835Z","updated_at":"2025-02-25T16:08:10.551Z","phase":"Phase 1/2","brief_title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","source_id_and_acronym":"NCT03611868 - Keynote MK-3475-B66","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" ATM mutation • TP53 wild-type","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • alrizomadlin (APG-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 08/29/2018","start_date":" 08/29/2018","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 03/30/2025","study_completion_date":" 03/30/2025","last_update_posted":"2024-07-19"},{"id":"114d9c89-e0e5-473e-a324-f2022f9b4244","acronym":"","url":"https://clinicaltrials.gov/study/NCT04465643","created_at":"2021-01-18T21:27:49.677Z","updated_at":"2025-02-25T14:29:26.270Z","phase":"Phase 1","brief_title":"Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor","source_id_and_acronym":"NCT04465643","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20","pipe":"","alterations":" ","tags":["PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/08/2021","start_date":" 06/08/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-06-21"},{"id":"f8a566d4-1220-4795-a41e-999d20763d92","acronym":"","url":"https://clinicaltrials.gov/study/NCT05245500","created_at":"2022-02-18T14:52:54.785Z","updated_at":"2024-07-02T16:34:59.606Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion","source_id_and_acronym":"NCT05245500","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" MTAP","pipe":"","alterations":" ","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navlimetostat (BMS‐986504)"],"overall_status":"Recruiting","enrollment":" Enrollment 370","initiation":"Initiation: 06/02/2022","start_date":" 06/02/2022","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2024-06-03"},{"id":"7315975a-48e7-478f-a922-63b5c722e7c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03872427","created_at":"2021-01-18T19:05:39.832Z","updated_at":"2024-07-02T16:35:03.365Z","phase":"Phase 2","brief_title":"Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study","source_id_and_acronym":"NCT03872427","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" STK11 • NF1 • KEAP1 • NFE2L2","pipe":" | ","alterations":" STK11 mutation • NF1 mutation • KEAP1 mutation • NFE2L2 mutation","tags":["STK11 • NF1 • KEAP1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation • NF1 mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e telaglenastat (CB-839)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 12/14/2019","start_date":" 12/14/2019","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2024-05-16"},{"id":"81497553-3d5a-49ef-8513-cf9cb5b29947","acronym":"","url":"https://clinicaltrials.gov/study/NCT05642455","created_at":"2022-12-08T14:57:33.766Z","updated_at":"2024-07-02T16:35:07.743Z","phase":"Phase 1/2","brief_title":"SPEARHEAD-3 Pediatric Study","source_id_and_acronym":"NCT05642455","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecelra (afamitresgene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 07/30/2038","study_completion_date":" 07/30/2038","last_update_posted":"2024-04-24"},{"id":"84a8bbc2-ef05-45fb-8d2a-c2429e123035","acronym":"STRIvE-02","url":"https://clinicaltrials.gov/study/NCT04483778","created_at":"2021-01-18T21:31:43.742Z","updated_at":"2024-07-02T16:35:07.947Z","phase":"Phase 1","brief_title":"B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","source_id_and_acronym":"NCT04483778 - STRIvE-02","lead_sponsor":"Seattle Children's Hospital","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression • CD19 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2040","study_completion_date":" 12/01/2040","last_update_posted":"2024-04-23"},{"id":"27578ddc-f283-4d0d-bcd4-108743a5b2fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04530487","created_at":"2021-01-18T21:41:28.381Z","updated_at":"2024-07-02T16:35:10.209Z","phase":"Phase 2","brief_title":"Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults","source_id_and_acronym":"NCT04530487","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV • melphalan • fludarabine IV • thiotepa • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/19/2020","start_date":" 08/19/2020","primary_txt":" Primary completion: 05/09/2025","primary_completion_date":" 05/09/2025","study_txt":" Completion: 05/09/2025","study_completion_date":" 05/09/2025","last_update_posted":"2024-04-11"},{"id":"e1485158-d730-462d-be42-9cd0f137d814","acronym":"STRIvE-01","url":"https://clinicaltrials.gov/study/NCT03618381","created_at":"2021-01-18T17:46:54.866Z","updated_at":"2024-07-02T16:35:10.845Z","phase":"Phase 1","brief_title":"EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","source_id_and_acronym":"NCT03618381 - STRIvE-01","lead_sponsor":"Seattle Children's Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 06/18/2019","start_date":" 06/18/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2040","study_completion_date":" 06/01/2040","last_update_posted":"2024-04-09"},{"id":"d92c2904-fae5-49ae-88c5-673b584f9118","acronym":"","url":"https://clinicaltrials.gov/study/NCT04872543","created_at":"2022-03-16T22:55:47.285Z","updated_at":"2024-07-02T16:35:16.749Z","phase":"Phase 2","brief_title":"A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)","source_id_and_acronym":"NCT04872543","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" SUZ12","pipe":" | ","alterations":" EZH2 mutation","tags":["SUZ12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 04/29/2021","start_date":" 04/29/2021","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-03-01"},{"id":"fff788d5-64ea-42a8-b069-9e2b5707d3ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03433183","created_at":"2021-01-18T16:56:06.010Z","updated_at":"2025-02-25T14:58:41.788Z","phase":"Phase 2","brief_title":"SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors","source_id_and_acronym":"NCT03433183","lead_sponsor":"Sarcoma Alliance for Research through Collaboration","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib) • sirolimus"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 10/02/2019","start_date":" 10/02/2019","primary_txt":" Primary completion: 06/22/2022","primary_completion_date":" 06/22/2022","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2023-12-25"},{"id":"bb6d3c5c-db8b-490f-9bee-af20d357f2d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05677594","created_at":"2023-01-10T15:59:31.004Z","updated_at":"2024-07-02T16:35:25.864Z","phase":"","brief_title":"Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1","source_id_and_acronym":"NCT05677594","lead_sponsor":"Johns Hopkins University","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2023-12-19"},{"id":"4d245490-7bad-40e7-abe3-a48c3f46369e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04774289","created_at":"2021-03-01T14:52:28.706Z","updated_at":"2024-07-02T16:35:31.672Z","phase":"","brief_title":"Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN)","source_id_and_acronym":"NCT04774289","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"],"overall_status":"Completed","enrollment":" Enrollment 296","initiation":"Initiation: 02/24/2021","start_date":" 02/24/2021","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 12/08/2022","study_completion_date":" 12/08/2022","last_update_posted":"2023-10-26"},{"id":"640b8ea4-dbbe-4ef7-aaf3-6fff167a55c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03009201","created_at":"2021-01-18T14:48:19.930Z","updated_at":"2025-02-25T15:53:37.006Z","phase":"Phase 1b","brief_title":"Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03009201","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 03/10/2017","start_date":" 03/10/2017","primary_txt":" Primary completion: 10/08/2019","primary_completion_date":" 10/08/2019","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2023-08-16"},{"id":"cc4fb18b-f792-4ae9-84d7-f106ddc4db2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04897321","created_at":"2021-05-21T11:52:50.695Z","updated_at":"2024-07-02T16:35:40.645Z","phase":"Phase 1","brief_title":"B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)","source_id_and_acronym":"NCT04897321","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/06/2022","start_date":" 07/06/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2023-08-08"},{"id":"ea505106-f0f3-438c-81cb-5a4b65a69585","acronym":"","url":"https://clinicaltrials.gov/study/NCT02452554","created_at":"2021-01-18T11:45:46.897Z","updated_at":"2024-07-02T16:36:18.487Z","phase":"Phase 2","brief_title":"Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma","source_id_and_acronym":"NCT02452554","lead_sponsor":"Children's Oncology Group","biomarkers":" NCAM1","pipe":" | ","alterations":" NCAM1 expression","tags":["NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lorvotuzumab mertansine (IMGN901)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 10/12/2015","start_date":" 10/12/2015","primary_txt":" Primary completion: 06/30/2017","primary_completion_date":" 06/30/2017","study_txt":" Completion: 09/30/2021","study_completion_date":" 09/30/2021","last_update_posted":"2022-01-13"},{"id":"ce51dd71-f581-4b05-8883-08013dc38521","acronym":"","url":"https://clinicaltrials.gov/study/NCT05107037","created_at":"2021-11-04T16:57:13.962Z","updated_at":"2024-07-02T16:36:21.312Z","phase":"Phase 1","brief_title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQ-B3234 in Patients With Type I Neurofibromatosis","source_id_and_acronym":"NCT05107037","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TQ-B3234"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2021-11-04"},{"id":"38f7e812-7b2f-4a13-9f7b-f337348cbfb4","acronym":"SARC023","url":"https://clinicaltrials.gov/study/NCT02008877","created_at":"2021-01-18T09:10:25.745Z","updated_at":"2024-07-02T16:36:59.593Z","phase":"Phase 1/2","brief_title":"SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)","source_id_and_acronym":"NCT02008877 - SARC023","lead_sponsor":"Sarcoma Alliance for Research through Collaboration","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus • sirolimus • ganetespib (ADX-1612)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 07/01/2018","study_completion_date":" 07/01/2018","last_update_posted":"2019-05-15"},{"id":"7ecea829-bf1f-4efa-8c59-704a89132c1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01661283","created_at":"2021-01-18T07:10:32.598Z","updated_at":"2025-02-25T15:52:55.396Z","phase":"Phase 2","brief_title":"SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors","source_id_and_acronym":"NCT01661283","lead_sponsor":"Sarcoma Alliance for Research through Collaboration","biomarkers":" NF1 • KDR","pipe":" | ","alterations":" NF1 mutation","tags":["NF1 • KDR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • everolimus"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 09/01/2012","start_date":" 09/01/2012","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2019-03-06"},{"id":"1143e6ad-4fb3-4eac-a9d3-83858e654c43","acronym":"","url":"https://clinicaltrials.gov/study/NCT01614795","created_at":"2021-01-18T06:55:05.325Z","updated_at":"2024-07-02T16:37:04.745Z","phase":"Phase 2","brief_title":"Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma","source_id_and_acronym":"NCT01614795","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" mTOR • IR","pipe":"","alterations":" ","tags":["mTOR • IR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 06/18/2012","start_date":" 06/18/2012","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 04/01/2014","study_completion_date":" 04/01/2014","last_update_posted":"2018-12-11"}]